BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10551434)

  • 1. Current strategies in the treatment of invasive Aspergillus infections in immunocompromised patients.
    Harari S
    Drugs; 1999 Oct; 58(4):621-31. PubMed ID: 10551434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
    Patterson TF; Kirkpatrick WR; White M; Hiemenz JW; Wingard JR; Dupont B; Rinaldi MG; Stevens DA; Graybill JR
    Medicine (Baltimore); 2000 Jul; 79(4):250-60. PubMed ID: 10941354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Guideline based treatment of invasive aspergillosis].
    Karthaus M
    Mycoses; 2010 May; 53 Suppl 1():36-43. PubMed ID: 20433655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of invasive aspergillosis].
    Martino P
    Mycoses; 1994; 37 Suppl 2():20-6. PubMed ID: 7609739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
    Castagnola E; Bucci B; Montinaro E; Viscoli C
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective.
    Kleinberg M
    Med Mycol; 2005 May; 43 Suppl 1():S289-94. PubMed ID: 16110822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin for treatment of invasive aspergillus infections.
    Heinz WJ; Einsele H
    Mycoses; 2008; 51 Suppl 1():47-57. PubMed ID: 18471161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
    Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
    J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS-aspergillosis: are there new treatment options?
    Schwartz S; Thiel E
    Mycoses; 2003; 46 Suppl 2():8-14. PubMed ID: 15055138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections.
    Mohammad RA; Klein KC
    Ann Pharmacother; 2006 Dec; 40(12):2148-54. PubMed ID: 17148653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive aspergillosis: new insights into disease, diagnostic and treatment.
    Karthaus M; Buchheidt D
    Curr Pharm Des; 2013; 19(20):3569-94. PubMed ID: 23278538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.
    Bellmann R
    Curr Pharm Des; 2013; 19(20):3629-47. PubMed ID: 23278532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aspergillosis in pulmonary transplantation].
    de Pablo A; Ussetti P; Cruz Carreño M; Lázaro T; Ferreiro MJ; López A; Mendaza P; Estada J
    Enferm Infecc Microbiol Clin; 2000 May; 18(5):209-14. PubMed ID: 10974763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.
    Stevens DA; Kan VL; Judson MA; Morrison VA; Dummer S; Denning DW; Bennett JE; Walsh TJ; Patterson TF; Pankey GA
    Clin Infect Dis; 2000 Apr; 30(4):696-709. PubMed ID: 10770732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of aspergillosis in immunocompromised patients. Recommendations of Lille University Hospital--4th version--November 2004].
    Alfandari S; Leroy O; de Botton S; Yakoub-Agha I; Durand-Joly I; Leroy-Cotteau A; Beaucaire G;
    Med Mal Infect; 2005 Mar; 35(3):121-34. PubMed ID: 15911182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Curative treatment of invasive aspergillosis].
    Dupont B
    Pathol Biol (Paris); 1994 Sep; 42(7):688-93. PubMed ID: 7877863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.